达雷妥尤单抗一线治疗在适合移植的新诊断多发性骨髓瘤患者中具有成本效益
本研究基于GRIFFIN和CASSIOPEIA试验中达雷妥尤单抗联合RVd或VTd提高MRD阴性率的结果,构建Markov模型以MRD状态预测无进展生存,从日本和美国支付方角度进行10年时间跨度的成本效益分析。日本分析中D-RVd较RVd的QALYs更高(5.43 vs 5.18)且成本更低(¥64 479,793 vs ¥71 287 569),D-VTd较VTd的QALYs更高(5.67 vs 5.42)且成本更低(¥43 600 310 vs ¥49 471,941);美国分析同样显示一线含达雷妥尤单抗方案占优。
要点
- 日本分析中D-RVd较RVd的QALYs更高(5.43 vs 5.18)且成本更低(¥64 479,793 vs ¥71 287 569)。
- 日本分析中D-VTd较VTd的QALYs更高(5.67 vs 5.42)且成本更低(¥43 600 310 vs ¥49 471,941)。
- 美国分析同样显示一线含达雷妥尤单抗方案占优。
核心结论
- 经济分析表明,将达雷妥尤单抗加入一线RVd和VTd方案,与将其留至二线使用相比,是占优策略。
研究设计与样本
- 成本效益分析,时间跨度10年,从日本和美国支付方角度计算QALYs和增量成本效益比。
- 因临床试验长期随访数据尚不可用,开发了以MRD状态预测无进展生存的Markov模型。
- 达雷妥尤单抗分别用于一线联合RVd或VTd,或二线联合卡非佐米加地塞米松(Kd)。
主要发现
- 日本分析中D-RVd较RVd的QALYs更高(5.43 vs 5.18)且成本更低(¥64 479,793 vs ¥71 287 569)。
- 日本分析中D-VTd较VTd的QALYs更高(5.67 vs 5.42)且成本更低(¥43 600 310 vs ¥49 471,941)。
- 美国分析同样显示一线含达雷妥尤单抗方案占优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triplet regimens, such as lenalidomide, bortezomib, and dexamethasone (RVd) or thalidomide, bortezomib, and dexamethasone (VTd), are standard induction therapies for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab to RVd and VTd has been investigated in the GRIFFIN and CASSIOPEIA trials, respectively, resulting in improvement in the rate of minimal residual disease (MRD) negativity. In this study, we conducted a cost-effectiveness analysis with a 10-year time horizon to compare first-line and second-line use of daratumumab for transplant-eligible patients with NDMM. Because long-term follow-up data for these clinical trials are not yet available, we developed a Markov model that uses MRD status to predict progression-free survival. Daratumumab was used either in the first-line setting in combination with RVd or VTd or in the second-line setting with carfilzomib plus dexamethasone (Kd). Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios were calculated from a Japanese and US payer perspective. In the Japanese analysis, D-RVd showed higher QALYs (5.43 vs 5.18) and lower costs (¥64 479,793 vs ¥71 287 569) compared with RVd, and D-VTd showed higher QALYs (5.67 vs 5.42) and lower costs (¥43 600 310 vs ¥49 471,941) compared with VTd. Similarly, the US analysis demonstrated dominance of a strategy incorporating daratumumab in first-line treatment regimens. Given that overall costs are reduced and outcomes are improved when daratumumab is used as part of a first-line regimen, the economic analysis indicates that addition of daratumumab to first-line RVd and VTd regimens is a dominant strategy compared with reserving its use for the second-line setting.
引用
- Yamamoto C, Minakata D, Koyama S, et al. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood. 2022. PMID: 35580269. doi:10.1182/blood.2021015220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。